The popular series profiling business innovators on Fox Business, Bloomberg, and A&E builds on its 13 years of success with a companion audio show offering a deeper dive into the stories of visionary entrepreneurs and trend-defining companies.
LOS ANGELES, CALIFORNIA / ACCESS Newswire / September 9, 2025 / “Trending Today,” the acclaimed TV series airing on Fox Business, Bloomberg, and A&E, announces a new podcast as a “sister show” to the long-running TV series. The audio show offers listeners a more relaxed yet in-depth exploration of the influential business leaders behind brands like Samsung, TurboTenant, and Tommy Bahama, and Tori Dunlap @herfirst100k, a New York Times best-selling author and host of the #1 money podcast for women, Financial Feminist.
“Trending Today” is the go-to series for an insider’s look into the entrepreneurial spirit driving some of the biggest global brands and personalities. “Trending Today” has received multiple Telly awards and recognition from the Los Angeles Film Awards, the Vegas Television and Movie Awards, and the Lonely Wolf Film Festival.
“We’re thrilled to expand the ‘Trending Today’ brand with the launch of ‘The Trending Today Podcast,’” said Executive Producer Liz Plummer. “Our television show has always given audiences a first look at innovators and entrepreneurs shaping the future, and now the podcast offers our guests a longer format to dive deeper into their stories, insights, and vision. It’s an exciting new way for us to give these leaders the platform they deserve.”
In Season 1, the “Trending Today Podcast” will highlight exciting stores from brands like Samsung, TurboTenant, Tommy Bahama, Jiffy, Ravin Consultants, Vivid Seats, SYNT, YNG Aesthetics and The House of She, Financial Feminist and more.
Listeners will hear firsthand from the executives behind some of the most prominent brands featured on the show, sharing valuable lessons from their journeys. Excerpts highlight the intense work and dedication behind the scenes that builds incredible brands, and conversations center around what it takes to reach seemingly overnight success.
In an episode exploring the live event space, Stan Chia, CEO of Vivid Seats, North America’s largest online ticketing platform, shared his insights consumer trust: “When I think about the live event space and what people are looking for, I think people are always looking for a platform that is secure and one you can trust.”
Brad Leavitt, CEO and founder of A Finer Touch Construction, a major player in luxury custom homes, emphasizes the importance of teamwork and collaboration: “Surrounding yourself with great people is really the key. That’s part of the hard work.”
Doug Wood, CEO of Tommy Bahama, discusses the importance of personal accountability and learning from mistakes: “Some of the worst decisions that are made are the ones you choose, that you didn’t make, and you just let something happen.”
Other notable episodes include:
From Prison to Purpose: Scott Curley’s Redemption Story
Financial Feminism with Tori Dunlap
Skin & Soul with Bree Gionta and Amy Cunningham
The “Trending Today Podcast” is growing quickly and new episodes are available on all major podcast platforms, including Spotify, Apple Podcasts, Podbean, and Overcast.
Subscribe to the podcast across your favorite listening platform, rate and review to support the show, and share guest or topic suggestions to shape future episodes. To learn more about “Trending Today,” visit https://trendingtoday.com/.
About “Trending Today”
“Trending Today,” the acclaimed television series airing on A&E, Bloomberg, and Fox Business, captures the entrepreneurial ambition that drives innovation around the world. Each episode highlights the latest technologies, market trends, and groundbreaking ideas through a thoughtfully selected lineup of inventors, innovators, and thought leaders. Crossing a wide range of industries, including consumer products, luxury lifestyles, health, and technology, “Trending Today” features companies and people who are pushing boundaries and redefining excellence. To learn more, visit www.trendingtoday.com.
Proprietary safety intelligence creates dual value: faster therapeutic development and biodefense.
LOS ANGELES, CALIFORNIA / ACCESS Newswire / September 9, 2025 / Lunai Bioworks Inc. (NASDAQ:RENB), an AI-powered drug discovery and biodefense company, today announced the launch of a transformer-based platform that embeds biological risk intelligence directly into large language model (LLM) pipelines. This breakthrough uses virtual chemical screening to identify novel compounds as being potentially toxic, expediting therapeutic discovery and development. Through its application, this platform also addresses a growing security concern, the misuse of generative AI in designing hazardous biological or chemical compounds.
With generative AI rapidly transforming healthcare and biotech, investors and regulators are increasingly focused on the dual-use challenge: the same algorithms that discover new medicines could also be exploited to create novel toxins. Lunai Bioworks’ solution embeds a proprietary neurotoxicity intelligence layer into LLM workflows, ensuring safety while preserving innovation.
“This is all about understanding and predicting risk,” said Dr. Gabe Musso, Chief Scientific Officer of Lunai Bioworks’ wholly owned subsidiary Biosymetrics Inc. “Our platform accelerates the discovery of safe, effective therapeutics, with the added benefit of being able to safeguard against the creation of novel chemical threats. That’s a major differentiator for our partners.”
Key investment highlights:
Exclusive Data Advantage: Powered by our large in vivo neurotoxicity datasets, collected from thousands of zebrafish-based assays, offering biological realism unmatched by public or in silico-only resources.
Defensible Technology: Transformer-based safety intelligence acts as a real-time safeguard within generative AI pipelines, creating a strong moat in a high-growth sector.
Massive Market Opportunity: Supports dual markets – multi-billion-dollar drug discovery AI and biodefense AI – both undergoing rapid expansion driven by government, pharma, and biotech demand.
Alignment with Global Priorities: Addresses urgent calls from regulators, governments, and AI safety organizations for robust safeguards against AI-enabled biothreats.
Scalable Partnerships: Positioned for integration with pharmaceutical pipelines, biotech platforms, and government biodefense programs.
By merging biodefense preparedness with pharmaceutical innovation, Lunai Bioworks Inc. is building a dual-purpose transformer for safe generative biology. This positions the company as a category leader at the convergence of AI, healthcare, and security.
About Lunai Bioworks
Lunai Bioworks Inc. is an AI-powered drug discovery and biodefense company pioneering safe and responsible generative biology. With proprietary neurotoxicity datasets, advanced machine learning, and a focus on dual-use risk management, Lunai is redefining how artificial intelligence can accelerate therapeutic innovation while safeguarding society from emerging threats.
Acquisition expands agent-driven analytics and storytelling as GoodData advances enterprise data intelligence.
SAN FRANCISCO, CA / ACCESS Newswire / September 9, 2025 / GoodData, the AI-native analytics platform, today announced its acquisition of Understand Labs, a pioneer in data storytelling and agentic analytics experiences. This acquisition strengthens GoodData’s foundation for delivering explainable, human-centered, AI-driven insights and accelerates the company’s roadmap toward the next generation of enterprise intelligence.
Founded in 2021 by Peter Fedorocko, co-founder and former CTO of Stories.bi (later acquired by Workday), Understand Labs has been at the forefront of solving the critical “last mile” challenge in analytics: helping businesses not just see data, but truly understand it. Their flagship SDKs power custom data storytelling solutions for industries including e-commerce, retail, logistics, and media.
“We believe analytics must go beyond charts and dashboards to deliver real, actionable intelligence. By combining Understand Labs’ storytelling technology with GoodData’s AI-native platform, we’re accelerating the industry’s move toward agentic, explainable, and decision-driven analytics,” said Roman Stanek, Founder and CEO of GoodData. “This acquisition is an important step toward our vision of making AI a trusted, everyday partner for every business user.”
Through this acquisition, GoodData will enhance its platform, leading to faster insight-to-action for business teams and a broader adoption of AI across GoodData’s customer base. By leveraging Understand Labs’ expertise, GoodData will be able to:
Improve AI-generated narratives related to explainability, key drivers, and natural language engagement.
Accelerate integrating agentic workflows directly into dashboards and data experiences.
Provide new options for business users when it comes to guided decision-making and engagement points.
“Over the last six months, we’ve had the opportunity to collaborate with GoodData on several complex enterprise projects. It was incredible to see how GoodData’s developer-friendly, composable platform amplified our ability to deliver unconventional, agentic applications,” said Peter Fedorocko, Founder & CEO of Understand Labs, and now Field CTO at GoodData. “Joining forces allows us to combine our deep expertise in augmented analytics with GoodData’s robust platform, perfectly positioned for the upcoming era of enterprise intelligence.”
Looking Ahead
The acquisition accelerates GoodData’s roadmap by bringing agent-driven analytics and storytelling components to market faster. Customers will benefit from more powerful natural language experiences, including richer narratives, explainable recommendations, and advanced key driver analysis. And GoodData will continue to expand its agentic analytics capabilities throughout 2025, with an upcoming launch that will showcase the first wave of tailor-made, embedded AI agents.
About GoodData
GoodData is the AI-native analytics platform built for speed, scale, and trust, helping companies deliver real-time insights – embedded, branded, and everywhere your users need them.
Founded in 2007, and with offices in both the U.S. and Europe, GoodData serves over 140,000 of the world’s top companies and 3.2 million users, helping them drive meaningful change and maximize the value of their data.
VANCOUVER, BC / ACCESS Newswire / September 9, 2025 / 1933 Industries Inc. (the “Company” or “1933 Industries”) (CSE:TGIF)(OTCID:TGIFF), a Nevada-focused cannabis cultivator and producer, is pleased to announce that it has closed the previously announced (see news release dated September 2, 2025) Debenture Repurchase Agreement (the “Agreements”) with two arm’s length parties (together the “Vendors“), for the repurchase and cancellation of a portion of Company’s outstanding unsecured convertible debentures.
Pursuant to the Agreements, the Company repurchased $475,000 in principal value of debentures for a total cash consideration of $47,500 CAD. Following the closing, the debentures were transferred, cancelled and removed from the Company’s outstanding liabilities.
The Agreement was conducted in accordance with the provisions of the trust indenture dated December 31, 2023, applicable securities laws, and the policies of the Canadian Securities Exchange (the “CSE“).
About 1933 Industries Inc.
1933 Industries is a Nevada-based licensed producer, focused on the cultivation and extraction of a large portfolio of cannabis consumer products in a variety of formats under its flagship brands, Alternative Medicine Association (AMA) and Level X. Its product offerings are cultivated at the Company’s 68,000 sq. ft. indoor facility and marketed directly to retail dispensaries. AMA branded flower, infused pre-rolls, and in-house boutique concentrates consistently rank as the top products sold in Nevada. For more information, please visit www.1933industries.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com. 1933 Industries undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.
SHELTON, CONNECTICUT / ACCESS Newswire / September 9, 2025 / NanoViricides, Inc. (NYSE American:NNVC ) (the “Company”), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that it will be presenting on Wednesday, September 17th, at 12:30pm at the Life Science Executive Partnering (“LSX”) World Congress 2025 in Boston, MA.
Event Information:
Event
NanoViricides Presentation at the LSX World Congress, 2025, Boston, MA
Day & Date
Wednesday, September 17, 2025
Time
12:30 pm
Location
LSX Biotech ShowCase (Day 2), Thomas Michael Menino (Boston) Convention and Exhibition Center, Boston, MA.
Anil R. Diwan, PhD, President and Executive Chairman of the Company will provide an update on the Company, its Drug Pipeline and Platform Technologies available for licensing.
Dr. Diwan has several pre-scheduled meetings in the partnering sessions and will also be available for meetings during the Congress on September 16th and 17th outside his busy schedule.
NanoViricides’ Current Antiviral Drugs Pipeline
The nanoviricides™ platform technology is yielding novel antiviral drug candidates against a number of challenging viral targets at a rapid pace.
Our most advanced candidate, NV-387, is an ultra-broad-spectrum antiviral with potential activity against most respiratory human pathogenic viruses – and more, because it emulates the attachment receptor family of sulfated proteoglycans that over 90% of human viruses utilize.
Moreover, NV-387 is designed to shape-shift upon binding to the virus particle, in the process disrupting the virus particle and making it incapable of infection, as a complete chemical nanomachine that destroys the virus.
The revolutionary broad antiviral spectrum of NV-387 is reminiscent of the dawn of antibiotics to combat bacterial infections.
Viruses are unlikely to escape NV-387 because no matter how much a virus evolves, it continues to utilize and require binding to sulfated proteoglycans – the very characteristic that NV-387 emulates. This solves the long-standing problem of antiviral medicines, that viruses escape them. Vaccines, antibodies and small chemical drugs are readily escaped by viruses as the viruses evolve in the field. This has been repeatedly observed during the recent COVID-19 pandemic, as well as in the course of most of the other viral epidemics including Influenza and HIV/AIDS.
Continued redevelopment or “updating” of vaccines necessitated by the viral escape or drift has recurrently cost billions of dollars every year for Influenza as well as COVID. NV-387 promises to make such costly endeavors unnecessary, once this drug is approved by regulatory bodies.
NV-387 is rapidly moving towards Phase II Safety, Tolerability and Efficacy Evaluation for the Treatment of MPOX disease, in response to the continuing Public Health Emergency of International Concern in WHO African Region. We already have received preliminary approval of the clinical protocol and the study and now we are working diligently to finish and submit the clinical trial application.
NV-387 was found to be highly effective against the “tripledemic” respiratory viruses, namely RSV, Influenza A, and Coronaviruses, in respective lethal animal models of lung infection. NV-387 was found to be substantially superior to existing drugs, and even resulted in complete cure in the RSV animal study.
Further, NV-387 has shown excellent effectiveness in lethal lung infection animal models relevant for Smallpox and MPox viruses.
Additionally, NV-387 has shown excellent effectiveness in lethal lung infection in a humanized (hCD150+ knock-in) mouse model by the Measles virus. Cases of Measles have been rapidly rising in the developing world including USA, Canada, UK and European countries. Measles is an important health threat because the disease can lead to “immune amnesia”, wiping out pre-developed immunity against other diseases, because it attacks the immune system itself.
At present, there are no generally approved drugs for the treatment of RSV, MPox, or Measles. The latter two are orphan diseases in the USA and will be eligible for earning a “Priority Review Voucher” (PRV) from the US FDA plus several years of market exclusivity upon approval. Each PRV is currently thought to be worth $150 million to $350 million as a tradable asset.
Additionally, NV-387’s success in treating MPox is expected to make it feasible to achieve US FDA regulatory approval as a Smallpox therapeutic, a much-needed drug for the US Bioterrorism defense strategy, with potential lucrative US Government and International contracts for stockpiling in the range of several hundred millions of dollars, assuming NV-387 is successful in a Phase II clinical trial for MPox treatment.
The overall market size of NV-387 indications is estimated to be well in excess of $10 billion.
NV-387 is expected to become an “emperic therapy” for viral infections, just as antibiotics such as amoxicillin are used as emperic therapies for bacterial infections.
NV-387 would be the first ever drug enabling emperic antiviral therapy, and would be potentially as revolutionary to antiviral therapy as antibiotics have been to anti-bacterial therapy. Emperic therapy means when the patient presents to the doctor, immediately the antiviral drug can be prescribed and started without having to wait for discriminating test results as to which virus is causing the infection. This has tremendous benefits since antiviral drugs are most effective when given as early as possible upon viral infection.
In addition, the Company has developed a clinical-ready pan-herpesvirus drug candidate, NV-HHV-1 that has shown activity against HSV-1, HSV-2 and VZV, and is expected to have activity against CMV, HHV-6, and HHV-8 as well.
The Company has also developed an anti-HIV drug candidate, NV-HIV-1, that has shown strong efficacy in SCID-hu-Thy-Liv animal model of HIV infection. NV-HHV-1 mimics the landing site on cellular CD4 that is required for all HIV viruses to cause cellular infection. Thus, HIV, despite constant changes, will be unable to escape NV-HHV-1.
NanoViricide Platform Enables Drug Rescue, Oral Drug Delivery, and Zip-Code Specific Delivery
Oral drug delivery of small chemicals, peptides (such as the GLP-a obesity drugs), and proteins is feasible by encapsulation of the guest drug into the nanoviricide polymeric micelle. The encapsulation protects the guest from metabolism thereby enabling effective drug delivery.
Encapsulation of a difficult or failed drug within the nanoviricide polymeric micelle can enable rescue of the drug candidate turning it into a clinically viable drug candidate, saving hundreds of millions of dollars of development work.
Going another step further, the nanoviricide platform technology can be customized to enable zip-code-like specific delivery of encapsulated drugs to specific tissues (e.g. non-liver targeted delivery),, cells (e.g. cancer-cell specific delivery sparing normal cells), bacteria, or viruses (e.g. NV-HHV-1, NV-HIV-1) in a fully synthetic chemistry based, scalable technology stack.
Life Science Executive Partnering (LSX) World Congress will be held on Sept 16-17, with Forums on Sept 15, 2025, at the Thomas Michael Menino Convention & Exhibition Center, Boston, USA.
What is LSX World Congress-USA ? LSX World Congress-USA is where innovators, investors and senior life science dealmakers in the LSX community connect, learn and partner. The Congress gathers leaders from the US biotech, medtech, and pharmatech sectors to network, showcase innovations, and explore partnership opportunities. It offers a unique platform for CEOs, investors, and pharma executives to engage in meaningful discussions and collaborative sessions, shaping the future of healthcare technology. Empowering innovation, accelerating investment and facilitating partnering to shape the future of healthcare is the objective of LSX World Congress.
NanoViricides, Inc. (the “Company”) (www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.
The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.
Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.
NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.
The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.
This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
The phrases “safety”, “effectiveness” and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.
FDA refers to US Food and Drug Administration. IND application refers to “Investigational New Drug” application. cGMP refers to current Good Manufacturing Practices. CMC refers to “Chemistry, Manufacture, and Controls”. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency’s (EMA) committee responsible for human medicines. API stands for “Active Pharmaceutical Ingredient”. WHO is the World Health Organization. R&D refers to Research and Development.
New preclinical findings highlight Telomir-1’s ability to reverse CDKN2A gene silencing by DNA methylation, reactivating this gene – often called the body’s natural “cell cycle brake.” These results build on prior STAT1 data, supporting Telomir-1’s profile as a potential first-in-class broad-spectrum DNA methylation reset therapy.
MIAMI, FLORIDA / ACCESS Newswire / September 9, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a preclinical-stage biotechnology company developing therapies that target the root causes of biological aging, cancer, and age-related diseases, today announced new preclinical cancer data showing that Telomir-1 reverses DNA methylation of CDKN2A, a master tumor suppressor gene silenced in many aggressive cancers.
Reactivating Cancer’s Brakes CDKN2A is one of the body’s most important natural defenses against cancer. Often called the “cell cycle brake,” this gene tells cells when to stop dividing and helps damaged cells self-destruct. In many cancers, CDKN2A is switched off by abnormal DNA methylation, leaving tumors free to grow unchecked. By resetting this methylation, Telomir-1 appears to turn the brake back on – restoring a critical safeguard that cancer cells had disabled.
Why DNA Methylation Matters DNA methylation is a key epigenetic process that controls whether genes are switched on or off. In healthy cells, methylation helps regulate normal development and repair. In cancer, however, abnormal DNA methylation can silence critical tumor suppressor genes like CDKN2A and STAT1, allowing tumors to grow unchecked and evade the immune system. Similarly, widespread changes in DNA methylation patterns are recognized as one of the hallmarks of aging, contributing to the loss of cellular function and the onset of age-related diseases.
By demonstrating the ability to reduce DNA methylation of these important targets, Telomir-1 is showing potential to directly address these fundamental biological processes. This positions Telomir-1 not only as a novel oncology candidate, but also as a potential first-in-class longevity drug candidate targeting the root causes of aging and disease.
In aggressive human prostate cancer cell models (PC3 xenografts), Telomir-1 inhibited CDKN2A DNA methylation more effectively than both Rapamycin and chemotherapy. These results complement Telomir’s previously reported data showing that Telomir-1 also resets STAT1, a master regulator of immune surveillance. Together, these findings suggest that Telomir-1 may broadly reverse cancer-induced silencing of key tumor suppressors – tackling two of cancer’s most fundamental escape mechanisms: unchecked growth and immune evasion.
CEO Perspective “This new evidence reinforces Telomir-1’s potential as a first-in-class longevity drug candidate that addresses the root causes of aging and age-related diseases through its ability to reset abnormal DNA methylation patterns,” said Erez Aminov, Chief Executive Officer of Telomir. “By demonstrating that Telomir-1 can reverse cancer-induced gene silencing in tumor suppressors such as CDKN2A and STAT1, we are beginning to show how epigenetic reprogramming may restore fundamental cellular functions that are disrupted in both cancer and aging.”
Scientific Perspective “These findings are highly significant,” said Dr. Itzchak Angel, Chief Scientific Advisor at Telomir. “By simultaneously reactivating STAT1 and CDKN2A, Telomir-1 demonstrates the ability to reset epigenetic silencing across multiple tumor suppressor pathways. This dual restoration of both immune surveillance and cell cycle control represents a powerful mechanistic advance in cancer epigenetics and provides a compelling rationale for further translational development.”
Advancing Toward the Clinic Telomir is actively assessing Telomir-1 across multiple aggressive cancers beyond prostate, with additional studies underway. The company’s pre-IND program is running in full gear, with CMC activities scaling up toward GMP production and IND-enabling studies ongoing as Telomir moves toward its first IND submission.
Cautionary Note Regarding Forward-Looking Statements This press release, statements of Telomir’s management or advisors related thereto, and the statements contained in the news story linked in this release contain “forward-looking statements,” which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1.
Any forward-looking statements in this press release are based on Telomir’s current expectations, estimates and projections only as of the date of this release. These and other risks concerning Telomir’s programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which are on file with the SEC and available at www.sec.gov. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Inaugural Atlanta gathering brings together emerging leaders from major financial institutions
NEW YORK CITY, NY / ACCESS Newswire / September 9, 2025 / Vero Technologies, a leading provider of modular lending technology solutions, and Accend, an AI-powered credit and underwriting platform, today announced the launch of their NextGen Leaders Dinner Series, an exclusive forum designed to connect and empower the next generation of decision-makers in wholesale and asset finance.
The inaugural dinner, scheduled for September 17, 2025 in Atlanta, will bring together carefully selected rising executives from leading financial institutions including Stellantis Financial Services, GM Financial, Ally, Yamaha Motor Finance, and Northpoint Commercial Finance. The evening will feature an intimate roundtable discussion facilitated by Marguerite Watanabe, Principal of Connections Insights Consulting and a recognized industry thought leader.
“The asset finance industry is at an inflection point, and the leaders who will drive the next wave of innovation are already in our organizations today,” said John Mizzi, CEO and Co-founder of Vero Technologies. “This dinner series creates a unique space for these emerging leaders to connect, share perspectives, and shape the future of our industry together. We’re not just hosting a dinner – we’re building a community of changemakers.”
The NextGen Leaders Dinner Series focuses on professionals who are poised to become tomorrow’s decision-makers. The Atlanta event marks the first in a series of exclusive gatherings planned across major financial hubs throughout 2025 and 2026.
“Traditional industry events often miss the voices that will define our future,” said Pranjal Daga, CEO and Co-founder of Accend. “By bringing together these rising stars in an intimate setting, we’re facilitating the conversations and connections that will drive real transformation in how financial institutions approach credit, risk, and AI adoption.”
The invitation-only event reflects a growing recognition that the next generation of asset finance leaders needs forums designed specifically for their unique perspectives and challenges, separate from traditional industry conferences dominated by current C-suite executives.
About Accend Accend is an AI-powered platform transforming credit and underwriting for modern financial institutions. By leveraging advanced machine learning and automation, Accend helps lenders make faster, more accurate credit decisions while reducing operational complexity.
About Vero Technologies Vero Technologies is a leading financial technology platform for asset finance, providing end-to-end solutions for wholesale finance, trade finance, equipment finance, and title management. Vero’s modular platform enables lenders to streamline loan servicing, risk monitoring, and operational workflows, enhancing efficiency while reducing costs.
HOUSTON, TX / ACCESS Newswire / September 9, 2025 / Monkey Island LNG (“MILNG”) has signed a Memorandum of Understanding (MOU) with an investment-grade natural gas supplier to support Phase 1 (15.6 MTPA) of MILNG’s proposed LNG export facility located in Cameron Parish, Louisiana. While the supplier’s name remains confidential, the agreement validates the significant support Monkey Island LNG has attracted from top-tier natural gas suppliers. It also marks a pivotal step on the path towards Final Investment Decision (FID), advancing MILNG’s commercial progress and further de-risking its approximately $25 billion infrastructure plan.
“Securing a 20-year commitment from a major supplier represents another critical milestone for Monkey Island LNG,” said Greg Michaels, CEO of MILNG. “MILNG’s proprietary TrueCost LNG™ model is designed to upend traditional opaque LNG pricing by delivering full transparency, lower lifecycle costs, and complete alignment of interests between producer, buyer, and investors. We look forward to building on this partnership and welcoming additional suppliers to join us in reshaping how LNG projects are structured and contracted globally.”
The company’s transparent TrueCost LNG™ model continues to resonate with global partners seeking clarity in pricing, alignment in incentives, and long-term reliability in supply. The MILNG executive team is currently engaging with additional natural gas suppliers to expand its feedstock portfolio and further de-risk its project development.
“With the project’s technology selected, fuel supply secured, and market demand validated, we’re executing on all pillars required to advance the project to FID,” added Michaels. “This is LNG done differently – and done right.”
The project’s strategic location in Louisiana and its 246-acre site offers direct access to prolific natural gas production basins and deepwater marine access, enabling highly efficient logistics and low-cost LNG exports. MILNG sits approximately 70 miles from Henry Hub, the U.S. natural gas distribution hub and the benchmark pricing point for natural gas futures on the New York Mercantile Exchange (NYMEX).
Key Highlights
20-year gas supply secured with investment-grade supplier
Built on MILNG’s proprietary TrueCost LNG™ model for cost transparency and commercial alignment
Supports Phase 1 of MILNG’s 15.6 MTPA LNG export project
Project is located near Henry Hub with direct access to prolific gas basins and deepwater marine routes
MILNG facility will use ConocoPhillips’ (“COP”) Optimized Cascade® liquefaction technology
Signed Master Services Agreement with McDermot for engineering and planning services
About Monkey Island LNG
Monkey Island LNG (“MILNG”) is a private company addressing the global energy crisis and growing demand for LNG through the development of critically needed U.S. natural gas infrastructure. Its flagship project, located on Monkey Island in Cameron Parish, Louisiana, sits just 2 miles inland from the Gulf of Mexico near abundant gas supply and features a proven and stable liquefaction technology of COP, an innovative commercial structure, and a low-cost construction plan leveraging an industry-proven EPC contractor. For more information, go to www.monkeyislandlng.com.
Forward-Looking Statement
This communication contains forward-looking statements within the meaning of applicable securities laws. All statements, other than statements of historical fact, are forward-looking statements and involve risks, uncertainties, and assumptions. These include, without limitation, statements regarding the expected scope, design, and timing of the Monkey Island LNG project; the execution, terms, and timing of definitive agreements; anticipated commercial progress; and other future events or developments.
Although Monkey Island LNG (“MILNG”) believes the expectations expressed in such forward-looking statements are reasonable, there can be no assurance that they will prove correct. Forward-looking statements are based on current assumptions and are subject to a number of risks and uncertainties, many of which are beyond our control. These risks include, but are not limited to: changes in market conditions, credit and capital markets, and industry norms; failure to successfully execute or complete contracts; changes in project scope, design, or schedules; availability of qualified personnel and resources; contract modifications, cancellations, or disputes; and other factors that could cause actual results to differ materially from those expressed or implied.
Forward-looking statements speak only as of the date of this communication. MILNG undertakes no obligation to update or revise any forward-looking statements to reflect events or circumstances after the date hereof, except as required by applicable law. Readers are cautioned not to place undue reliance on forward-looking statements.
Press Contacts
For Monkey Island LNG: Greg Michaels, CEO, Monkey Island LNG Greg.m@mkyisland.com 949-636-5900
– Gemini normalized the inflammatory response at the cellular level in stage 3 and 4 CKD patients –
– Gemini could potentially revolutionize the treatment of acute and chronic inflammatory disease –
Data discussion webcast/conference call will be held on Wednesday, September 10th at 8:30 am Eastern Time
SAN DIEGO, CA / ACCESS Newswire / September 9, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company focused on rebalancing inflammation, today announced positive safety and activity data for its Phase 1b PRIME clinical study in stage 3 and 4 chronic kidney disease (CKD) patients. The primary endpoint to evaluate the safety and tolerability of escalating doses of Gemini was met.
More importantly, Gemini significantly reduced inflammatory activity and restored normal cellular response to stimuli as measured in peripheral blood mononuclear cells (PBMCs) isolated from patients at predose, 2, 24, and 168 hours post-dose, demonstrating Gemini’s ability to durably rebalance the inflammatory process at the cellular level. Revelation will host a corporate update webcast/conference call on Wednesday, September 10th at 8:30 am Eastern Time to review this top-line data and the potential impact of the use of Gemini for the treatment of acute and chronic inflammatory diseases.
“The activity observed with a single dose of Gemini in patients is shocking,” said Principal Investigator Adam Horeish, MD, Balboa Research. “This effect suggests a meaningful step forward in addressing the underlying immune dysregulation observed in patients with chronic kidney disease, and I am intrigued by the potential of Gemini to treat multiple types of acute and chronic inflammation.”
“The results from this Phase 1b study represent a possible breakthrough in the treatment of inflammation,” said Principal Investigator Pablo Pergola, MD, PhD,Research Director at Clinical Advancement Center, PLLC. “By addressing the inflammatory component of CKD, we may be able to improve patient outcomes and bring meaningful benefit to those living with this challenging condition. We look forward to working with the Revelation team to advance Gemini as a potential treatment for CKD.”
“The clear results from the PRIME study demonstrate the power of Gemini to elicit trained immunity,” said Julia K. Bohannon, Ph.D., Associate Professor, Department of Anesthesiology, Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center. “It is highly validating to see results consistent with the findings from our animal studies, as I would have expected. The strength of the effect of a single dose reinforces my confidence in the potential of Gemini as a promising treatment for burn patients.”
The PRIME study enrolled 40 patients from 32 to 78 years of age, at 3 US clinics located in San Diego and San Antonio, specializing in the care of patients with CKD. A total of 5 cohorts (8 patients per cohort, 6 treated/2 placebo) at 4 dose levels were enrolled: a subtherapeutic dose, a low dose, the target dose (cohorts 3 and 4), and a high dose – an extension protocol was conducted to collect additional PBMC and biomarker samples in 8 Gemini naive or secondary naive patients. The primary endpoint was evaluation of safety.
In addition to safety measures, patient PBMCs were isolated predose and at 2, 24, and 168 hours post-dose. PBMCs were analyzed ex vivo for background inflammation by measurement of IL-1β, TNF-α, IL-6, IL-10, and IL-1RA. Cells were also assessed for response to stimulation by lipopolysaccharide (LPS, also known as endotoxin) or high mobility group box-1 protein (HMGB1). Subgroup analysis divided patients into two categories, those with PBMCs of minimal background inflammation activity (£40 pg/mL IL-1β) and normal response to stimuli, and those with significant background inflammation activity (>40 pg/mL IL-1β) and no response to stimuli. Approximately 50% of patients were in each group.
In patients with high background PBMC activity, Gemini significantly reduced inflammation relative to placebo patient PBMCs post dose (IL-1β: p0.01; TNF-α: p=0.05; IL-6: p0.01; IL-10: p0.01; IL-1RA: p0.001) and remained significantly below their baseline value through 7 days. Background inflammation was reduced to levels comparable to PBMCs isolated from healthy subjects.
Additionally, Gemini was able to demonstrate correction of the immunoparalysis typical to chronic disease. Gemini significantly increased the responsiveness to LPS stimulation in high background patient PBMCs relative to placebo at all timepoints (IL-1β: p0.0001; TNF-α: p0.002; IL-6: p0.0002; IL-10: p=0.09; IL-1RA: p0.01). Gemini also significantly increased the responsiveness of patient PBMCs with high background vs placebo patient PBMCs with high background at all time-points to HMGB1 stimulation (IL-1β: p0.05; TNF-α: p0.01; IL-6: p0.01; IL-10: p0.05; IL-1RA: p0.002). The increased responsiveness was comparable to PBMCs isolated from healthy subjects. These results show the ability of Gemini to restore normal cell function, even as far as one week after a single dose.
For the low background patients, as expected, Gemini does not increase inflammatory activity. Additional analysis on the effect of LPS or HMGB-1 stimulation is ongoing.
Gemini administration was well-tolerated at the target dose (established as the maximum tolerated dose in healthy volunteers) with all events reported as mild (Grade I). Adverse events observed at the target dose included transient headache, chills, loose stool, and body aches. Three adverse events at the highest dose (above the target dose) were reported as severe (Grade III), and included chills, nausea and vomiting, all resolving in 3 hours or less. Other reported events were either mild (Grade I) or moderate (Grade II). All events corresponded with the previous healthy volunteer study, as well as with preclinical findings, and are consistent with the expected pharmacology of the drug. No serious adverse events were reported. Gemini administration did not result in clinically significant trends in clinical safety blood or urinalysis parameters (aside from expected immune cell mobilization). There were no clinically significant changes or trends in vital sign parameters or ECG assessments following administration of Gemini.
“The results of the PRIME study demonstrate the potential of Gemini to be a game-changer in the treatment of acute and chronic inflammation,” said James Rolke, Chief Executive Officer of Revelation. “We look forward to our scheduled End of Phase 1 meeting with the FDA later this year to discuss the advancement of this exciting program.”
The September 10th webcast at 8:30 am Eastern Time can be accessed here, or to call in, please dial 888-506-0062 (toll free in the US), +1 973-528-0011 (if International) and use participant access code 289672. A copy of the slides being presented in the webcast can be found on Revelation’s website here.
Revelation will seek to publish these results and those from ongoing additional data analysis. For more information please visit www.RevBiosciences.com.
About CKD
Chronic kidney disease is a pervasive problem in the United States and world-wide. CKD is due to chronic inflammation and can be initiated and propagated in several ways. One prevalent condition is the high blood sugar levels associated with diabetes (either Type 1 or Type 2). High blood sugar is toxic to kidney cells creating stress which imitates the inflammatory process leading to the demise of these cells with subsequent fibrosis, ultimately resulting in continuous loss of kidney function over time. High arterial blood pressure is another source of stress that initiates the inflammatory process leading to CKD. Other risk factors include heart disease, obesity, family history of CKD, or advanced age. Progression of chronic kidney damage often leads to end stage renal disease with the need for renal replacement therapy (dialysis or transplantation), resulting in significant morbidity and mortality for affected patients. Kidney disease is a leading cause of death in the United States.
About Gemini
Gemini is the Company’s proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD®), a toll-like receptor 4 (TLR4) agonist. TLR4 stimulation with Gemini rebalances the innate immune response. Gemini is being developed as a treatment and a prevention of acute and chronic diseases associated with dysregulated inflammation.
About Revelation Biosciences, Inc.
Revelation Biosciences, Inc. is a clinical stage life sciences company focused on rebalancing inflammation using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including as a prevention for post-surgical infection, as prevention for acute kidney injury and for the treatment of chronic kidney disease.
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions. We caution investors that forward-looking statements are based on management’s expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward looking statements, which speak only as of the date they were made. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Revelation to meet its financial and strategic goals, due to, among other things, competition; the ability of Revelation to grow and manage growth profitability and retain its key employees; the possibility that the Revelation may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Revelation’s product candidates; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected initiation of the clinical studies, the timing of clinical data; the outcome of the clinical data, including whether the results of such study is positive or whether it can be replicated; the outcome of data collected, including whether the results of such data and/or correlation can be replicated; the timing, costs, conduct and outcome of our other clinical studies; the anticipated treatment of future clinical data by the FDA, the EMA or other regulatory authorities, including whether such data will be sufficient for approval; the success of future development activities for its product candidates; potential indications for which product candidates may be developed; the ability of Revelation to maintain the listing of its securities on NASDAQ; the expected duration over which Revelation’s balances will fund its operations; and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the SEC by Revelation.
Company Contact
Mike Porter Investor Relations Porter LaVay & Rose Inc. Email: mike@plrinvest.com
VANCOUVER, BC / ACCESS Newswire / September 9, 2025 / Avino Silver & Gold Mines Ltd. (TSX:ASM)(NYSE American:ASM)(FSE:GV6) a long-standing silver producer in Mexico, is proud to announce that Avino has been included in the Toronto Stock Exchange’s 2025 TSX30™. Avino has distinguished itself by reaching the 5th position on the TSX30 2025 ranking, which is a flagship program recognizing the 30 top-performing TSX stocks on a dividend-adjusted share price appreciation over a three-year period.
“I am extremely pleased that Avino has been recognised by the TSX in 2025,” said David Wolfin, Avino’s President and CEO. “For the three years ended June 30, 2025, Avino’s share price performance has increased 610% and market capitalization has increased 778%. These achievements reflect the decisive steps we took to prioritize Avino’s transformational growth and our plans to go from one to three producing assets by 2029. These results are a testament to the commitment, determination and hard work of all Avino’s employees. Our focus has been on advancing our operations in Mexico and strengthening our silver, gold, and copper profile as we progress toward becoming a leading intermediate producer. We remain focused on our growth objectives and committed to delivering long-term value for our shareholders and stakeholders.”
“The 2025 TSX30™ captures the evolution of our capital markets, where companies are scaling to compete globally for market share and capital. These top performers represent diverse sectors unified by strategic positioning and proven execution,” said Loui Anastasopoulos, CEO, Toronto Stock Exchange. “Together, this list highlights how companies are capitalizing on prevailing economic trends, with investors prioritizing sustainable value creation from companies with proven business models and strong cash flow generation, whether in transformative technologies or our world-class resource and industrial sectors.”
About Avino
Avino is a silver producer from its wholly owned Avino Mine near Durango, Mexico. The Company’s silver, gold and copper production remains unhedged. The Company intends to maintain long term sustainable and profitable mining operations to reward shareholders and the community alike through our growth at the historic Avino Property and the strategic acquisition of the adjacent La Preciosa which was finalized in Q1 2022. Early in 2024, the pre-feasibility Study on the Oxide Tailings Project was completed. This study is a key milestone in our growth trajectory. As part of Avino’s commitment to adopting sustainable practices, we have been operating a dry-stack tailings facility for more than two years with excellent results. We are committed to managing all business activities in a safe, environmentally responsible, and cost-effective manner, while contributing to the well-being of the communities in which we operate. We encourage you to connect with us on X (formerly Twitter) at @Avino_ASM and on LinkedIn at Avino Silver & Gold Mines. To view the Avino Mine VRIFY tour, please click here.
This news release contains “forward-looking information” and “forward-looking statements” (together, the “forward looking statements”) within the meaning of applicable securities laws and the United States Private Securities Litigation Reform Act of 1995, including the mineral resource estimate for the Company’s Avino Property, including La Preciosa, located near Durango in west-central Mexico (the “Avino Property”) with an effective date of October 16, 2023 and can be viewed within Avino’s latest technical report dated February 5, 2024 for the Pre-feasibility Study and references to to Measured, Indicated Resources, and Proven and Probable Mineral Reserves referred to in this press release. This information and these statements, referred to herein as “forward-looking statements” are made as of the date of this document. Forward-looking statements relate to future events or future performance and reflect current estimates, predictions, expectations or beliefs regarding future events and include, but are not limited to, statements with respect to: (i) the estimated amount and grade of mineral reserves and mineral resources, including the cut-off grade; (ii) estimates of the capital costs of constructing mine facilities and bringing a mine into production, of operating the mine, of sustaining capital, of strip ratios and the duration of financing payback periods; (iii) the estimated amount of future production, both ore processed and metal recovered and recovery rates; (iv) estimates of operating costs, life of mine costs, net cash flow, net present value (NPV) and economic returns from an operating mine; and (v) the completion of the full Technical Report, including a Preliminary Economic Assessment, and its timing. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives or future events or performance (often, but not always, using words or phrases such as “expects”, “anticipates”, “plans”, “projects”, “estimates”, “envisages”, “assumes”, “intends”, “strategy”, “goals”, “objectives” or variations thereof or stating that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative of any of these terms and similar expressions) are not statements of historical fact and may be forward-looking statements. These forward-looking statements are made as of the date of this news release and the dates of technical reports, as applicable. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the future circumstances, outcomes or results anticipated in or implied by such forward-looking statements will occur or that plans, intentions or expectations upon which the forward-looking statements are based will occur. While we have based these forward-looking statements on our expectations about future events at the date that such statements were prepared, the statements are not a guarantee that such future events will occur and are subject to risks, uncertainties, assumptions and other factors which could cause events or outcomes to differ materially from those expressed or implied by such forward-looking statements.
